Strategic Collaboration for Commercialization of Progenza
Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza
Overview of collaboration
Under the terms of the agreement, Regeneus grants AGC exclusive rights to manufacture Progenza in Japan and a 50 percent interest in Regeneus Japan, which has the exclusive rights for the clinical development and commercialisation of Progenza in Japan for osteoarthritis and all therapeutic applications.
Regeneus will receive US$16.5 million from AGC, with US$5.5million as an upfront payment and the remaining $11m in specific development and approval milestone payments. Regeneus will also be entitled, through its 50% interest in the joint venture, to its share of upfront licence fees, milestone payments and royalties from sub licensing the development and commercialization of Progenza for osteoarthritis and all other clinical indications in Japan.
AGC will be responsible for funding the manufacture of Progenza for the proposed Phase 2 trial for osteoarthritis in Japan under specific conditions.
About Asahi Glass Co., Ltd
AGC (Asahi Glass Co Ltd) (TYO:5201) solves everyday challenges with its world-leading, cutting-edge technologies. Using the world's top-class technologies cultivated through a history of technological innovation extending over 100 years, AGC has continued to achieve the creation of new values in the business areas of Glass, Electronics, Chemicals, and Ceramics.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.
Asahi Glass Co., Ltd